zolbetuximab
astellas
[]
#spotlight data by at #gi23: #zolbetuximab+mfolfox6 as 1l for cldn18.2+ her2- advanced gc/gej pfs and os orr teaes: nausea/vomiting (on target) cldn18.2+ in 38.5% of pts, and pd-l1 cps 5 in 13.2%
first positive biomarker-selected ph3 trial in gc in&gt;10 years 
Research fellow @SarahCannon_UK/@EarlyCancerCam & Medical Oncology Resident @HumanitasMilano. GI cancers passionate, illustrations lover.